- Current report filing (8-K)
January 13 2010 - 5:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 13,
2010
BRUKER CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-30833
|
|
04-3110160
|
(State or other
jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
40
Manning Road
Billerica,
MA 01821
(Address of principal
executive offices)(Zip Code)
Registrants
telephone number, including area code:
(978) 663-3660
Check
the appropriate box if the Form 8-K filing is intended to simultaneously
satisfy the reporting obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act
o
Soliciting material pursuant
to Rule 14a-12 of the Exchange Act
o
Pre-commencement
communications pursuant to Rule 14d-2(b) Exchange Act
o
Pre-commencement communications
pursuant to Rule 13e-4(c) Exchange Act
Item 2.02 Results
of Operations and Financial Condition.
On January 13, 2010,
Bruker Corporation (the Company) will participate in the 28
th
Annual J.P.
Morgan Healthcare Conference in San Francisco, California. The presentation materials, a copy of which
are attached hereto as Exhibit 99.1, on slide 8 contain previously
non-public information relating to preliminary, unaudited revenue estimates and
other financial results for the recently completed fourth quarter of fiscal
2009 and on slide 17 contain previously non-public information relating to 2009
order bookings at the Companys Bruker Daltonics subsidiary.
The information in this Current
Report on Form 8-K, including
exhibits
attached hereto
and the information under Item 7.01 below,
is being furnished and shall not
be deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that Section and shall not be deemed incorporated by
reference into any filing by the Company under the Securities Act of 1933, as
amended, or the Exchange Act, unless specifically identified therein as being
incorporated by reference therein.
Item 7.01 Regulation
FD Disclosure.
The information set forth in Item 2.02 is incorporated
herein in its entirety. The slides that will accompany Company managements
presentation at the above-referenced conference, attached to this Current
Report on Form 8-K as Exhibit 99.1, are also posted on the
Companys investor relations website at http://www.bruker.com.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. 99.1
January 13,
2010 Presentation at the 28
th
Annual J.P. Morgan Healthcare
Conference
.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
BRUKER CORPORATION
(Registrant)
|
|
|
|
Date: January 13,
2010
|
By:
|
/s/Frank H. Laukien
|
|
|
Frank H.
Laukien, Ph.D.
Chief Executive Officer and President
|
3
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024